SLC5A2 and chronic kidney disease: Recent RCTs, including CREDENCE, DAPA-CKD, and EMPA-KIDNEY (Supplementary Table 1), have provided compelling evidence that the combination of SGLT2 inhibitors and RAS inhibitors in individuals with type 2 diabetes mellitus results in a decreased risk of kidney and cardiovascular endpoint events (155–160).